Drug Profile
Research programme: anticancer therapeutics - S*BIO
Alternative Names: EX2; EX44; EX45; EX58; SB1304; SB1354; SB2312; SB2602Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator S*BIO
- Developer National University of Singapore; S*BIO
- Class Small molecules
- Mechanism of Action Cyclin-dependent kinase inhibitors; Enzyme inhibitors; Fms-like tyrosine kinase 3 inhibitors; Histone deacetylase inhibitors; Janus kinase-2 inhibitors; MTOR protein inhibitors; Phosphotransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Singapore (PO)
- 29 Aug 2013 This programme is still active
- 31 Mar 2010 Pacritinib, pracinostat, CT 1578, TG 02 and VS 5584 have been outlicensed prior to March 2010